ERBB2 and breast carcinoma: Shukla et al. have suggested that the various effects of phenolic compounds in cancer cell lines depend on cell prototypes (e.g., breast cancer cells with different epithelial growth factor receptors (HER2/neu) have different responses to phenolic compound treatments) [59].